Rheumatoid Arthritis

Dr. Jack Cush reviews the news, journal reports, ACR and FDA announcements from the past week on RheumNow.com First In Class, TYK2 Inhibitor FDA Approved for Psoriasis 2022 New ACR Guidance…

It has certainly been an interesting EULAR congress, with lots of new data emerging on both novel and extant treatments. Something which really struck me was the data on two topical approaches.…

By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around (lots of sneaker mileage)!  And congrats to…

A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon.  The latter covering topics like sarcoidosis,…

EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones…

It’s good to be back into full, big meeting mode. Multinational throngs of half-masked people, long security lines, limited seating, obstructed views, an abundance of little coffee options, no food…

Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic. It is well known that seropositivity for rheumatoid…